The One Shot That Crashes Your LDL Instantly

Patient arm with IV line in a hospital chair — Photo: goodbishop / Shutterstock

One shot in the arm cut bad cholesterol by more than half, and the effect was still holding more than a year later.

Quick Take

A single infusion of an experimental gene-editing drug called VERVE-102 lowered LDL cholesterol by up to 62 percent in an early human trial.
The drug permanently switches off a gene called PCSK9, which normally raises cholesterol levels in the blood.
Only 35 patients have been tested so far, and the longest follow-up is about a year and a half.
Scientists warn that permanent gene edits can carry risks that take years, even decades, to show up.

A Cholesterol Pill Replaced By A Single Shot

Millions of Americans take a cholesterol pill every single day for the rest of their lives. Eli Lilly’s experimental drug VERVE-102 aims to end that routine with one infusion. In a phase 1b study called Heart-2, researchers gave the treatment to 35 adults with inherited high cholesterol or early heart disease. The drug targets PCSK9, a gene that raises LDL, the “bad” cholesterol tied to heart attacks and strokes.

The results, reported by Lilly, showed PCSK9 protein levels dropped between 51 and 88 percent depending on the dose. LDL cholesterol fell by as much as 62 percent after just one treatment. For comparison, daily statin pills typically lower LDL by 30 to 50 percent, and patients have to keep taking them forever. This one-time approach uses base editing, a precise tool that flips a single genetic letter to permanently disable the PCSK9 gene in liver cells.

Fifteen of the 35 patients have now been followed for at least a year, and their cholesterol reductions appear to be holding steady, not fading like a drug wearing off. No patient died or suffered a dose-limiting injury. Seven had mild infusion reactions, and three showed temporary liver enzyme changes that resolved on their own. For a disease that quietly kills through decades of artery damage, that durability is the whole appeal.

Why A Permanent Fix Comes With A Permanent Question

Editing a gene is not like stopping a pill. Once PCSK9 is switched off, it stays off for life. That permanence is the selling point, but it is also the catch. Scientists studying gene therapy broadly have found that some dangerous side effects do not appear for years. In one widely cited case, two patients developed cancer five years after receiving a different gene therapy for sickle-cell disease, forcing researchers to pause related trials.

Other research has shown that when gene-editing tools stay active in cells longer than planned, unwanted edits in the wrong parts of the genome can keep piling up even after the intended edit is done. A separate review found rare but real cases of scrambled DNA segments showing up in patients who got CRISPR-based treatments, and noted that a year or two of follow-up simply cannot tell doctors what will happen ten or twenty years down the road.

Sek Kathiresan, a researcher involved in cardiovascular gene editing, put it plainly: the biology behind these drugs is well understood, but long-term safety is still a work in progress that will take years to establish. That is not fear-mongering. It is the honest tradeoff of trading a reversible daily pill for an irreversible one-time edit. Federal regulators take this seriously enough that they recommend monitoring gene-editing patients for up to 15 years after treatment, specifically to catch problems that take time to surface.

What Comes Next Before This Reaches Your Medicine Cabinet

None of this means VERVE-102 is dangerous. It means the evidence so far answers one question, not two. It proves the drug can slash a cholesterol-raising gene’s activity and keep LDL down for over a year. It does not yet prove the drug prevents heart attacks or strokes, because that requires tracking patients far longer and comparing them against people on standard treatment.

A similar one-patient CRISPR success story made headlines this year when doctors corrected a rare, deadly metabolic disorder in an infant using a custom-built gene edit, allowing the baby to eat normal food without a medical crisis. These cases show the science works in principle. What remains is the unglamorous part: years of follow-up, independent replication outside the drug company funding the trial, and larger studies built to catch rare harms before this reaches the general public.

For now, patients with inherited high cholesterol have reason for real hope, and reason for patience. A future where a single infusion replaces a lifetime of pills is not science fiction anymore. But getting there safely means resisting the urge to call this a cure before the data has had time to prove it.